To investigate the early effects of IL-23 inhibition, we obtained serial, full-thickness skin biopsies from five individuals with psoriasis who had achieved skin clearance (remission) by 16 weeks of risankizumab treatment (Supplementary Table 1, Fig. 1A, B). The gene discussed is IL23A; the disease is psoriasis.